Warfarin Anticoagualtion for liver fibrosis in patients transplanted for hepatitis C virus infection. - WAFT-C

Phase 1

• Conditions: iver fibrosis in patients infected with hepatitis C virus after liver transplantation.; MedDRA version: 9.1Level: HLTClassification code 10019669Term: Hepatic fibrosis and cirrhosis; MedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis C; MedDRA version: 9.1Level: LLTClassification code 10010186Term: Complications of transplanted liver

• Registration Number: EUCTR2006-006221-77-GB
• Lead Sponsor: Clinical Research office, Faculty of Medicine, Imperial College London

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-05-30
• Study Completion: 2012-07-01
• Last Update Posted: 13 October 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. HCV infection.

2. Age >17.

3. Liver transplant within previous 4 months.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Patients requiring anticoagulation for existing clinical indications.

2. Standard contraindications to anticoagulation (active peptic ulcer disease, past history of haemorrhagic stroke, thrombocytopaenia (Platelets count < 90 x109 /L).

3. Large oesophageal varices persisting post-transplant.

4. Known cerebrovascular abnormalities.

5. HIV antibody positive.

6. Baseline fibrosis score of 2 or greater.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified